AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
1965 - On 5th February, the Company entered into an agreement with C.H. Boehringer Sohn, Ingelheim am Rhein (also known as Hoehringer Ingelheim GmbH) who agreed to give the Company free of royalty ...
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...
Merck Animal Health, Ceva, Zoetis, and Boehringer Ingelheim GmbH are a few of Europe’s key players in the Global Swine ...
In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...
Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...
Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
To our knowledge, this is the first intestinal ultrasound appropriateness rating exercise conducted for defining, diagnosing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback